Search

Your search keyword '"Brianti, Pina"' showing total 41 results
Start Over Author "Brianti, Pina"
41 results on '"Brianti, Pina"'

1. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis).

Author

Gargiulo, Luigi, Ibba, Luciano, Ingurgio, Ruggero Cascio, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E., Caproni, Marzia, Carrera, Carlo G., Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V., Dini, Valentina, and Gaiani, Francesca M.

Subjects
BODY weight, PSORIASIS, RETROSPECTIVE studies
Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-tosevere plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200mg versus tildrakizumab 100mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200mg and 364 patients treated with tildrakizumab 100mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90kg or a high disease burden (Psoriasis Area and Severity Index [PASI]≥16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16weeks of treatment with tildrakizumab 200mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200mg has better effectiveness than tildrakizumab 100mg in patients with a body weight ≥ 90kg and a high disease burden. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Gender influence and bimekizumab treatment in moderate-to-severe psoriasis: a short term real-life multicenter experience

Author

Diotallevi, F, Richiardi, I, Shevchuk, A, Esposito, M, Vagnozzi, E, Concetta Fargnoli, M, Gisondi, P, Bellinato, F, Assorgi, C, Orsini, D, Brianti, P, Raffaele Mercuri, S, Burlando, M, Cozzani, E, Brunasso, G, Caccavale, S, Di Caprio, R, Balato, A, Caldarola, G, De Simone, C, Campione, E, Giunta, A, Calzavara Pinton, P, Venturini, M, Giovanni Carrera, C, Valerio Marzano, A, Carugno, A, Sena, P, Costanzo, A, Narcisi, A, Cusano, F, Dapavo, P, Quaglino, P, Dattola, A, Giovanni Richetta, A, Gaiani, F, Malagoli, P, Megna, M, Potestio, L, Mortato, E, Loconsole, F, Romano, F, Faragalli, A, Gesuita, R, Campanati, A, Diotallevi, Federico, Richiardi, Irene, Shevchuk, Anna, Esposito, Maria, Vagnozzi, Emanuele, Concetta Fargnoli, Maria, Gisondi, Paolo, Bellinato, Francesco, Assorgi, Chiara, Orsini, Diego, Brianti, Pina, Raffaele Mercuri, Santo, Burlando, Martina, Cozzani, Emanuele, Brunasso, Giovanna, Caccavale, Stefano, Di Caprio, Roberta, Balato, Anna, Caldarola, Giacomo, De Simone, Clara, Campione, Elena, Giunta, Alessandro, Calzavara Pinton, Piergiorgio, Venturini, Marina, Giovanni Carrera, Carlo, Valerio Marzano, Angelo, Carugno, Andrea, Sena, Paolo, Costanzo, Antonio, Narcisi, Alessandra, Cusano, Francesco, Dapavo, Paolo, Quaglino, Pietro, Dattola, Annunziata, Giovanni Richetta, Antonio, Gaiani, Francesca, Malagoli, Piergiorgio, Megna, Matteo, Potestio, Luca, Mortato, Edoardo, Loconsole, Francesco, Romano, Francesca, Faragalli, Andrea, Gesuita, Rosaria, Campanati, Anna, Diotallevi, F, Richiardi, I, Shevchuk, A, Esposito, M, Vagnozzi, E, Concetta Fargnoli, M, Gisondi, P, Bellinato, F, Assorgi, C, Orsini, D, Brianti, P, Raffaele Mercuri, S, Burlando, M, Cozzani, E, Brunasso, G, Caccavale, S, Di Caprio, R, Balato, A, Caldarola, G, De Simone, C, Campione, E, Giunta, A, Calzavara Pinton, P, Venturini, M, Giovanni Carrera, C, Valerio Marzano, A, Carugno, A, Sena, P, Costanzo, A, Narcisi, A, Cusano, F, Dapavo, P, Quaglino, P, Dattola, A, Giovanni Richetta, A, Gaiani, F, Malagoli, P, Megna, M, Potestio, L, Mortato, E, Loconsole, F, Romano, F, Faragalli, A, Gesuita, R, Campanati, A, Diotallevi, Federico, Richiardi, Irene, Shevchuk, Anna, Esposito, Maria, Vagnozzi, Emanuele, Concetta Fargnoli, Maria, Gisondi, Paolo, Bellinato, Francesco, Assorgi, Chiara, Orsini, Diego, Brianti, Pina, Raffaele Mercuri, Santo, Burlando, Martina, Cozzani, Emanuele, Brunasso, Giovanna, Caccavale, Stefano, Di Caprio, Roberta, Balato, Anna, Caldarola, Giacomo, De Simone, Clara, Campione, Elena, Giunta, Alessandro, Calzavara Pinton, Piergiorgio, Venturini, Marina, Giovanni Carrera, Carlo, Valerio Marzano, Angelo, Carugno, Andrea, Sena, Paolo, Costanzo, Antonio, Narcisi, Alessandra, Cusano, Francesco, Dapavo, Paolo, Quaglino, Pietro, Dattola, Annunziata, Giovanni Richetta, Antonio, Gaiani, Francesca, Malagoli, Piergiorgio, Megna, Matteo, Potestio, Luca, Mortato, Edoardo, Loconsole, Francesco, Romano, Francesca, Faragalli, Andrea, Gesuita, Rosaria, and Campanati, Anna

Published
2024

3. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

Author

Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, Costanzo, Antonio, Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, and Costanzo, Antonio

Abstract

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

Published
2024

4. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra, Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, and Narcisi, Alessandra

Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.

Published
2024

5. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Author

David Carbone, Michael Sharpnack, Kai He, Lisa H. Butterfield, Alexander M. M. Eggermont, Maria Gonzalez-Cao, Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowskyj, Ana Giménez-Capitán, Cristina Teixidó, Miguel Angel Molina-Vila, Santiago Viteri Ramírez, Salvador Martin Algarra, Elisabeth Pérez-Ruiz, Iván Márquez-Rodas, Delvys Rodriguez-Abreu, Remei Blanco, Teresa Puértolas, Maria Angeles Royo, Rafael Rosell, Maria Libera Ascierto, Svetlana Hamm, Tanja Wulff, Kerstin Kronthaler, Sabine Schrepfer, Ulrike Parnitzke, Anne Catherine Bretz, Roland Baumgartner, Veronica Ferrucci, Francesco Paolo Pennino, Luisa Dassi, Fatemeh Asadzadeh, Roberto Siciliano, Marianeve Carotenuto, Daniela Spano, Cristina Maria Chiarolla, Adelaide Greco, Monica Cantile, Maurizio Di Bonito, Gerardo Botti, Vandenbussche Jonathan, Gevaert Kris, Massimo Zollo, Teresa Amaral, Ioanna Tampouri, Ulrike Keim, Thomas Eigentler, Claus Garbe, Andrea Forschner, Alessandra Cesano, Sarah Warren, Duane Moogk, Kaitao Li, Zhou Yuan, Shi Zhong, Zhiya Yu, Ivan Liadi, William Rittase, Victoria Fang, Janna Dougherty, Arianne Perez-Garcia, Iman Osman, Navin Varadarajan, Nicholas P. Restifo, Alan Frey, Cheng Zhu, Michelle Krogsgaard, Claire Vanpouille-Box, Silvia C. Formenti, Sandra Demaria, Cristiana Lo Nigro, Alexander Renziehausen, Andreas G. Tzakos, Hexiao Wang, Bhavya Rao, Rubeta Matin, Catherine Harwood, Daniela Vivenza, Federica Tonissi, Marcella Occelli, Lynda Weir, Su Li, Van Ren Sim, Kevin O’Neill, Alan Evans, Alastair Thompson, Peter Szlosarek, Colin Fleming, Charlotte Proby, Nelofer Syed, Marco Merlano, Tim Crook, Robert Ferguson, Danny Simpson, Carlos Martinez, Matjaz Vogelsang, Esther Kazlow, Melissa Wilson, Anna Pavlick, Jeffrey Weber, Ryan Sullivan, Keith Flaherty, Antoni Ribas, Tomas Kirchhoff, Antonio D’Avino, Licia Guida, Augusto Cosacco, Roberta D’Aniello, Piera Maiolino, Teresa Tramontano, Maria R. Sarno, Ida Palazzo, Angela Di Napoli, Gianclaudio Acunzo, Mariarosanna De Fina, Antonia Silvestri, Monica Specchia, Michela Musacchio, Gianfranco Giglio, Francesco Carrozza, Liberato Di Lullo, Gian Marco De Maddi, Adele Venturelli, Elisabetta Gambale, Alessia Gatta, Davide Brocco, Consiglia Carella, Michele De Tursi, Thomas F. Gajewski, Costanza M. Cristiani, Rossana Tallerico, Valeria Ventura, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Eliska Selinger, Cinzia Garofalo, Elina Staaf, Ester Simeone, Antonio M. Grimaldi, Genny del Zotto, Elio Gulletta, Gennaro Ciliberto, Alessandro Moretta, Paolo A. Ascierto, Ennio Carbone, Susan Costantini, Angela Sorice, Francesca Capone, Alfredo Budillon, Carolina Cauchi, Grazia Sciancalepore, Michela Rovera, Chiara Varamo, Zelda Seia, Stefania Palazzini, Fabiana Errico, Davide Basso, Laura Quaranta, Giuseppe Forte, Fulvio Lavagna, Silvia Violante, Paolo Bosio, Laura Lattanzio, Marco C Merlano, Mike Gowen, Jeremy Tchack, Hua Zhou, Keith Giles, Scott Paschke, Una Moran, David Fenyo, Aris Tsirigos, Michael Pacold, Silvana Morello, Claudia Sorrentino, Diana Giannarelli, Aldo Pinto, Federica Fratangelo, Rosaria Falcone, Vito Vanella, Dirk Schadendorf, Karl Lewis, Michele Maio, Lev Demidov, Mario Mandalà, Igor Bondarenko, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant Goodman, Brian Simmons, Chenglin Ye, Gregory Hooper, Matthew J. Wongchenko, Yibing Yan, Frank Hermann, Astrid Ammendola, René Bartz, Bulotta Alessandra, Colombo Letizia, Mirabile Aurora, Lazzari Chiara, Mercuri Santo Raffaele, Parolini Danilo, Rizzo Nathalie, Martella Stefano, Modorati Giulio, Brianti Pina, Cestone Enza, Bellinzona Federica, Miserocchi Elisabetta, Gianni Luca, Gregorc Vanesa, Sanjiv Agarwala, B. Mark Smithers, Axel Haushild, Eric Watcher, Luigi Fattore, Ciro Francesco Ruggiero, Domenico Liguoro, Andrea Cerri, Maria Elena Pisanu, and Rita Mancini

Subjects
Medicine
Published
2018
Full Text
View/download PDF

6. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, Luigi, primary, Narcisi, Alessandra, additional, Ibba, Luciano, additional, Balato, Anna, additional, Bianchi, Luca, additional, Brianti, Pina, additional, Buononato, Dario, additional, Burlando, Martina, additional, Caldarola, Giacomo, additional, Campanati, Anna, additional, Campione, Elena, additional, Carrera, Carlo G., additional, Carugno, Andrea, additional, Cristaudo, Antonio, additional, Cusano, Francesco, additional, Dapavo, Paolo, additional, Dattola, Annunziata, additional, De Simone, Clara, additional, Gaiani, Francesca M., additional, Gisondi, Paolo, additional, Giunta, Alessandro, additional, Loconsole, Francesco, additional, Maione, Vincenzo, additional, Mortato, Edoardo, additional, Marzano, Angelo V., additional, Maurelli, Martina, additional, Megna, Matteo, additional, Mercuri, Santo R., additional, Offidani, Annamaria, additional, Orsini, Diego, additional, Parodi, Aurora, additional, Pellacani, Giovanni, additional, Potestio, Luca, additional, Quaglino, Pietro, additional, Richetta, Antonio G., additional, Romano, Francesca, additional, Sena, Paolo, additional, Venturini, Marina, additional, Malagoli, Piergiorgio, additional, and Costanzo, Antonio, additional

Published
2023
Full Text
View/download PDF

7. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

Author

Talamonti, Marina, primary, Russo, Filomena, additional, Malara, Giovanna, additional, Hansel, Katharina, additional, Papini, Manuela, additional, Cattaneo, Angelo, additional, Parodi, Aurora, additional, Chiricozzi, Andrea, additional, Malagoli, Piergiorgio, additional, Bardazzi, Federico, additional, Brazzelli, Valeria, additional, Dapavo, Paolo, additional, Gisondi, Paolo, additional, Zane, Cristina, additional, Potenza, Concetta, additional, Cantoresi, Franca, additional, Fargnoli, Maria Concetta, additional, Trevisini, Sara, additional, Brianti, Pina, additional, Pescitelli, Leonardo, additional, Gigante, Giovanni, additional, Bartezaghi, Marta, additional, Caputo, Luisa, additional, Aloisi, Elisabetta, additional, and Costanzo, Antonio, additional

Published
2023
Full Text
View/download PDF

8. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, Costanzo, Antonio, Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, and Costanzo, Antonio

Abstract

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

Published
2023

9. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

Author

Talamonti,Marina, Russo,Filomena, Malara,Giovanna, Hansel,Katharina, Papini,Manuela, Cattaneo,Angelo, Parodi,Aurora, Chiricozzi,Andrea, Malagoli,Piergiorgio, Bardazzi,Federico, Brazzelli,Valeria, Dapavo,Paolo, Gisondi,Paolo, Zane,Cristina, Potenza,Concetta, Cantoresi,Franca, Fargnoli,Maria Concetta, Trevisini,Sara, Brianti,Pina, Pescitelli,Leonardo, Gigante,Giovanni, Bartezaghi,Marta, Caputo,Luisa, Aloisi,Elisabetta, Costanzo,Antonio, Talamonti,Marina, Russo,Filomena, Malara,Giovanna, Hansel,Katharina, Papini,Manuela, Cattaneo,Angelo, Parodi,Aurora, Chiricozzi,Andrea, Malagoli,Piergiorgio, Bardazzi,Federico, Brazzelli,Valeria, Dapavo,Paolo, Gisondi,Paolo, Zane,Cristina, Potenza,Concetta, Cantoresi,Franca, Fargnoli,Maria Concetta, Trevisini,Sara, Brianti,Pina, Pescitelli,Leonardo, Gigante,Giovanni, Bartezaghi,Marta, Caputo,Luisa, Aloisi,Elisabetta, and Costanzo,Antonio

Abstract

Marina Talamonti,1 Filomena Russo,2 Giovanna Malara,3,4 Katharina Hansel,5 Manuela Papini,6 Angelo Cattaneo,7 Aurora Parodi,8 Andrea Chiricozzi,9,10 Piergiorgio Malagoli,11 Federico Bardazzi,12 Valeria Brazzelli,13 Paolo Dapavo,14 Paolo Gisondi,15 Cristina Zane,16 Concetta Potenza,17 Franca Cantoresi,18 Maria Concetta Fargnoli,19 Sara Trevisini,20 Pina Brianti,21 Leonardo Pescitelli,22 Giovanni Gigante,23 Marta Bartezaghi,23 Luisa Caputo,23 Elisabetta Aloisi,23 Antonio Costanzo24,25 On behalf of the SUPREME Study Group1Dermatology, University of Rome Tor Vergata, Rome, Italy; 2Department of Medical, Surgical and Neurological Science, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy; 3Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio, Calabria, Italy; 4Department of Dermatology, Papardo Hospital, Messina, Italy; 5Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 6Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 7U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 8Di.S.Sal. Section of Dermatology, Ospedale Policlinico San Martino, University of Genova, Genova GE, 16132, Italy; 9UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; 10Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; 11Psocare Unit, I.R.C.C.S Policlinico San Donato, Milano, Italy; 12Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 13Dermatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 14Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Torino, Torino, Italy; 15Section of Dermatology and Venereology, Department of Medicine, University

Published
2023

13. Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients

Author

Paolino, Giovanni, primary, Buratta, Sandra, additional, Mercuri, Santo R., additional, Pellegrino, Roberto M., additional, Urbanelli, Lorena, additional, Emiliani, Carla, additional, Bertuccini, Lucia, additional, Iosi, Francesca, additional, Huber, Veronica, additional, Brianti, Pina, additional, Prezioso, Caterina, additional, Di Nicola, Matteo R., additional, Federici, Cristina, additional, and Lugini, Luana, additional

Published
2022
Full Text
View/download PDF

21. A Case of Two Adult Brothers with Wiskott-Aldrich Syndrome, One Treated with Gene Therapy and One with HLA-Identical Hematopoietic Stem Cell Transplantation.

Author

Consiglieri, Giulia, Ferrua, Francesca, San Raffaele Hospital Consortium, Brianti, Pina, Peccatori, Jacopo, Markel, Sarah, Giglio, Fabio, Ladogana, Saverio, Notarangelo, Lucia Dora, Bernardo, Maria Ester, Ciceri, Fabio, Bognanni, Antonio, Migliavacca, Maddalena, Barzaghi, Federica, Calbi, Valeria, Tucci, Francesca, Gallo, Vera, Dionisio, Francesca, Giannelli, Stefania, and Cenciarelli, Sabina

Subjects
HEMATOPOIETIC stem cell transplantation, WISKOTT-Aldrich syndrome, MUCOSITIS, GENE therapy, ADULTS
Abstract

Over the past decade, ex vivo hematopoietic stem and progenitor cell gene therapy (HSPC-GT) using a lentiviral vector (LV) has resulted in an alternative treatment strategy for WAS patients without a suitable matched donor. The indication for allogeneic HSCT in WAS was initially restricted to patients with severe manifestations, while other patients were managed conservatively. Immune reconstitution was achieved in both patients, with earlier discontinuation of immunoglobulin supplementation in the patient treated with HSPC-GT. However, the choice of the most appropriate treatment should be tailored on the single patient, based on donor availability and careful evaluation of patient's specific risk-benefit profile. [Extracted from the article]

Published
2022
Full Text
View/download PDF

22. Metastatic Merkel cell carcinoma of the face

Author

Vaccaro, Mario, Magaudda, Emanuele, Brianti, Pina, Licata, Luana, Cardia, Roberta, and De Ponte, Francesco

Subjects
Merkel cell carcinoma -- Case studies -- Diagnosis -- Care and treatment, Head and neck cancer -- Case studies -- Diagnosis -- Care and treatment, Health
Abstract

Byline: Mario. Vaccaro, Emanuele. Magaudda, Pina. Brianti, Luana. Licata, Roberta. Cardia, Francesco. De Ponte Sir, Merkel cell carcinoma is a rare malignant neuroendocrine skin tumor, most common in the elderly [...]

Published
2016

33. CO2 laser and photodynamic therapy: Study of efficacy in periocular BCC.

Author

Mercuri, Santo Raffaele, Brianti, Pina, Dattola, Annunziata, Bennardo, Luigi, Silvestri, Martina, Schipani, Giusy, and Nisticò, Steven Paul

Subjects
*BASAL cell carcinoma, *SKIN cancer, *PHOTODYNAMIC therapy, *PUBLIC health, *MEDICAL care
Abstract

Abstract: Basal cell carcinoma (BCC), the most common type of skin cancer in the world, usually arises in sun‐exposed areas of the skin. The therapeutic approach to periocular BCC has changed in the last few years. Currently the treatment, considering the delicate localization of the disease, must not only ensure complete recovery from the neoplastic disease, but must also satisfy functional and aesthetic criteria. In this study we tried to evaluate the efficacy of CO2 laser and photodynamic therapy in periocular BCC. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

35. Acral pseudolymphomatous angiokeratoma of children (APACHE): Dermoscopic features and successful treatment with CO2 laser.

Author

Mercuri, Santo Raffaele, Bartolucci, Marco, Brianti, Pina, Paolino, Giovanni, and Rizzo, Nathalie

Subjects
ANGIOKERATOMA, CARBON dioxide lasers, TREATMENT effectiveness, STEROIDS, RADIOTHERAPY
Abstract

The article presents a case study of a 30-year-old white female, with a skin phototype II. It is noted that her diagnosis revealed that she was suffering from Acral pseudolymphomatous angiokeratoma of children (APACHE), a rare benign dermatosis also classified as pseudolymphoma. The article adds that patient underwent a treatment with CO2 laser, which proved effective as compared to Pulsed dye laser (PDL), topical , and radiotherapy.

Published
2018
Full Text
View/download PDF

36. The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

Author

Megna M, Orsini D, Assorgi C, Balato A, Balestri R, Bianchi L, Brianti P, Brunasso G, Buononato D, Burlando M, Cagni AE, Caldarola G, Cameli N, Campanati A, Campione E, Carrera CG, Carugno A, Chersi K, Costanzo A, Cusano F, D'Amico D, Dal Bello G, Dapavo P, Dattola A, De Simone C, Di Lernia V, Dini V, Errichetti E, Esposito M, Fargnoli MC, Fiorella CS, Foti A, Gaiani FM, Gargiulo L, Gatti A, Gisondi P, Giunta A, Ibba L, Lasagni C, Loconsole F, Maione V, Malagoli P, Marzano AV, Maurelli M, Mercuri SR, Michelerio A, Michelucci A, Morrone P, Mortato E, Narcisi A, Offidani A, Paolino G, Parodi A, Pellacani G, Quaglino P, Richetta AG, Romano F, Sena P, Trevisan G, Uzzauto MT, Venturini M, and Potestio L

Published
2024
Full Text
View/download PDF

37. Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

Author

Orsini D, Malagoli P, Balato A, Bianchi L, Brianti P, Buononato D, Burlando M, Caldarola G, Campanati A, Campione E, Carrera CG, Carugno A, Cusano F, Dapavo P, Dattola A, De Simone C, Dini V, Esposito M, Fargnoli MC, Gaiani FM, Gargiulo L, Gisondi P, Giunta A, Ibba L, Lasagni C, Loconsole F, Maione V, Mortato E, Marzano AV, Maurelli M, Megna M, Mercuri SR, Narcisi A, Offidani A, Paolino G, Parodi A, Pellacani G, Potestio L, Quaglino P, Richetta AG, Romano F, Sena P, Venturini M, Assorgi C, and Costanzo A

Abstract

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis., Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia., Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index., Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g = 0) within 16 weeks. Moreover, consistent improvements were observed in Psoriasis Area and Severity Index scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index, signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity., Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

Published
2024
Full Text
View/download PDF

38. Acral pseudolymphomatous angiokeratoma of children (APACHE): Dermoscopic features and successful treatment with CO 2 laser.

Author

Mercuri SR, Paolino G, Bartolucci M, Rizzo N, and Brianti P

Subjects
Adult, Angiokeratoma pathology, Dermoscopy, Female, Humans, Pseudolymphoma pathology, Skin Neoplasms pathology, Toes, Angiokeratoma diagnostic imaging, Angiokeratoma surgery, Lasers, Gas therapeutic use, Pseudolymphoma diagnostic imaging, Pseudolymphoma surgery, Skin Neoplasms diagnostic imaging, Skin Neoplasms surgery
Published
2018
Full Text
View/download PDF

39. CO 2 laser and photodynamic therapy: Study of efficacy in periocular BCC.

Author

Mercuri SR, Brianti P, Dattola A, Bennardo L, Silvestri M, Schipani G, and Nisticò SP

Subjects
Aged, Aged, 80 and over, Carcinoma, Basal Cell pathology, Chemotherapy, Adjuvant, Esthetics, Facial Neoplasms pathology, Female, Humans, Laser Therapy adverse effects, Lasers, Gas adverse effects, Male, Middle Aged, Patient Satisfaction, Photosensitizing Agents adverse effects, Skin Neoplasms pathology, Treatment Outcome, Tumor Burden, Carcinoma, Basal Cell therapy, Facial Neoplasms therapy, Laser Therapy instrumentation, Lasers, Gas therapeutic use, Photochemotherapy adverse effects, Photosensitizing Agents administration & dosage, Skin Neoplasms therapy
Abstract

Basal cell carcinoma (BCC), the most common type of skin cancer in the world, usually arises in sun-exposed areas of the skin. The therapeutic approach to periocular BCC has changed in the last few years. Currently the treatment, considering the delicate localization of the disease, must not only ensure complete recovery from the neoplastic disease, but must also satisfy functional and aesthetic criteria. In this study we tried to evaluate the efficacy of CO 2 laser and photodynamic therapy in periocular BCC., (© 2018 Wiley Periodicals, Inc.)

Published
2018
Full Text
View/download PDF

40. Quality of life of psoriasis patients measured by the PSOdisk: a new visual method for assessing the impact of the disease.

Author

Mercuri SR, Gregorio G, and Brianti P

Subjects
Adult, Age Factors, Aged, Female, Humans, Male, Middle Aged, Psoriasis drug therapy, Psoriasis psychology, Severity of Illness Index, Young Adult, Biological Products therapeutic use, Psoriasis physiopathology, Quality of Life
Abstract

Background: Psoriasis is an inflammatory disease with a chronic course; often it is associated with various serious comorbidity and a compromised quality of life. Psoriasis patients experience a low self-esteem, feelings of shame and frustration, they report a seriously compromised social and sentimental sphere, difficulties at work and in daily activities, coming in most serious cases to suicidal ideation., Methods: Our job is to experiment the introduction of the innovative PSOdisk tool to quantify the impact of psoriasis on quality of life, comparing it with PASI Index. We presented the empirical analysis, gathered through a sample of 24 patients, followed for 6 months of therapy with biologics. Patients were encountered three times, at a distance of three months each, during which we calculated a PASI score and we administered the PSOdisk., Results: Through various statistical analyses we have identified a relationship between PSOdisk value and other parameters such as patient age and particular locations of psoriasis. Specifically we systematically observed that patients aged less than 50 years reported a more compromised quality of life (QoL) when compared to older patients with the same clinical severity. At the same time patients with hands or genitals involvement show higher values associated with the PSOdisk compared with patients without such anatomical deficiency., Conclusions: PSOdisk instrument proved to be effective and optimal for widespread distribution in the outpatient activity. It also encourages dialogue between doctor and patient; it increases compliance of the latter with regard to the therapy and a desirable improvement in outcomes. A systematic assessment of the impact of psoriasis on patients' QoL is fundamental and must complement the objective assessment in clinical practice.

Published
2017
Full Text
View/download PDF

41. Review of HPV-related diseases and cancers.

Author

Brianti P, De Flammineis E, and Mercuri SR

Subjects
Genome, Viral, Humans, Papillomavirus Infections pathology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines immunology, Tumor Virus Infections pathology, Tumor Virus Infections prevention & control, Neoplasms virology, Papillomaviridae genetics, Papillomavirus Infections virology, Tumor Virus Infections virology
Abstract

Human papillomavirus (HPV) is a double-stranded circular DNA virus belonging to the papillomavirus family. It is transmitted by skin-to-skin or mucosa-to-mucosa contact and enters the body via cutaneous or mucosal trauma. HPV infection is the most common sexually transmitted disease, although it is usually cured by the immune system. Worldwide, the risk of being infected at least once in a lifetime among both men and women is 50%. HPV infection causes common and anogenital warts, as well as other non-dermatological diseases. The role of HPV in cancer development has been extensively studied, primarily in cervical cancer, but also in other types of neoplasms.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results